Disc Medicine, Inc. Number of Reporting Units
Disc Medicine, Inc. (IRON) reported Number of Reporting Units of 1 Segment for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:NumberOfReportingUnits · last filed 2026-02-26
- Disc Medicine, Inc. number of reporting units for the quarter ending 2025-03-31 was 1.00 Segment.
- Disc Medicine, Inc. number of reporting units for the quarter ending 2021-03-31 was 1.00 Segment.
- Disc Medicine, Inc. number of reporting units for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- Disc Medicine, Inc. number of reporting units for fiscal 2024 was 1.00 Segment, a 0.00% change from fiscal 2023.
- Disc Medicine, Inc. number of reporting units for fiscal 2023 was 1.00 Segment, a 0.00% change from fiscal 2022.
- Disc Medicine, Inc. number of reporting units for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Reporting Units 3 month | Number of Reporting Units 6 month | Number of Reporting Units 9 month | Number of Reporting Units 12 month |
|---|---|---|---|---|
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-03-21 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-03-31 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-03-10 | |||
| 2021-09-30 | 1.00 Segment 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 1.00 Segment 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 1.00 Segment 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |